Manthan Bhadiyadra
3.6K posts
Manthan Bhadiyadra
@ManthanTweets1
#Friends #Family #Investment #Health
เข้าร่วม Mayıs 2021
580 กำลังติดตาม2.4K ผู้ติดตาม
#Semicomp sheet. (re-posting because the table was not visible)
#Semiconductor
Logic Fabs
$TSM 19.8x
Samsung 5x
$INTC 63.1x
$GFS 26.2x
981:HK 40.9x
$UMC 17.5x
Memory
$WDC 27.9x
$STX 27.8x
$SNDK 10.9x
$MU 4.9x
000660:KS SK Hynix 3.8x
Analog, RFs
$TXN 29.9x
$ADI 30.9x
$IFNNY 22.4x
$MCHP 30.5x
$STM 21.2x
$ON 22x
Fabless
$NVDA 18.8x
$AVGO 23.6x
$QCOM 12.2x
$AMD 28.1x
(CoWOS is 1/2 of $NVDA, valuation is 1/9th of $NVDA ) - what twitter smarty pants crowd does not tell you.
$MRVL 30.2x
$NXPI 14.4x
$SWKS 12.2x
Research & Invest@R_and_Invest
#Semicomp sheet. #Semiconductor Logic Fabs $TSM 19.8x Samsung 5x $INTC 63.1x $GFS 26.2x 981:HK 40.9x $UMC 17.5x Memory $WDC 27.9x $STX 27.8x $SNDK 10.9x $MU 4.9x 000660:KS SK Hynix 3.8x Analog, RFs $TXN 29.9x $ADI 30.9x $IFNNY 22.4x $MCHP 30.5x $STM 21.2x $ON 22x Fabless $NVDA 18.8x $AVGO 23.6x $QCOM 12.2x $AMD 28.1x (CoWOS is 1/2 of $NVDA, valuation is 1/9th of $NVDA ) - what twitter smarty pants crowd does not tell you. $MRVL 30.2x $NXPI 14.4x $SWKS 12.2x
English
@R_and_Invest wish I had spent more time and reading on this man. looks like massive opp missed. :(
English
I cant imagine scenario where CHOPS becomes better product than OCS2.0 for heart and Lung. It is not possible clinically, they are trying to prove superiority. Competition is not ready to participate itself tells cold storage has no ground against OCS2.0. For short distance, CHOPS will take share from existing cold players so this is win
English
Is this new device a temporary or a permanent offering?
Clearly $TMDX won't make a product that would be better than their OCS system, or else that would ruin the trial results.
If it's permanent it could be a lower cost alternative to the more expensive OCS but I think it would come down to the margin economics. It would be a bit strange to offer it after all the talk about how inferior cold storage is, but perhaps this new device is still better.
Manthan Bhadiyadra@ManthanTweets1
$TMDX ‘Igloo’ box companies refused to provide their device to participate in OCS2.0 trials comparison for DBD Heart and Lung. Guess what Waleed did? Today TransMedics will unveil its new controlled, active cooling preservation device, the Controlled Hypothermic Organ Preservation System (CHOPS), aimed at facilitating the enrollment of the control arms of the OCS ENHANCE Heart Part B and OCS DENOVO Lung clinical trials. CHOPS will be regulated by the U.S. Food and Drug Administration (FDA) as a new, stand-alone device for controlled hypothermic preservation. Importantly, TransMedics will submit an Investigation Device Exemption (IDE) amendment to allow CHOPS to serve as the control arm for both Part B of ENHANCE Heart and DENOVO Lung Trials. if approved, this approach would also expand TransMedics' product offerings to include true controlled active cooling preservation devices to serve a broader segment of heart and lung transplant patients globally, based on prospective level 1 evidence. $TMDX enters in cooling preservation devices market as at the end of trials, they will have clinical evidence for OCS2.0 superiority AND alternative offering of Product that dominate DBD market today. So most probably, $TMDX will get PMI post trials for OCS2.0 and CHOPS.
English
@JonahLupton This was pleasant surprise wasn’t it? I didn’t thought they will end up with creating another business vertical and get it trialed in same boat without any meaningful cost. Plus now we will earn revenue for control arm😂😂 2027 and 2028 is very bright.
English
Manthan Bhadiyadra รีทวีตแล้ว
$TMDX How badass can the CEO/company be?
"Our competitors wouldn't cooperate as part of the clinical trial, so we created a device like theirs but made it superior and turned it into the Control arm. We are still going to beat it and replace them with either of our offerings."
Manthan Bhadiyadra@ManthanTweets1
$TMDX ‘Igloo’ box companies refused to provide their device to participate in OCS2.0 trials comparison for DBD Heart and Lung. Guess what Waleed did? Today TransMedics will unveil its new controlled, active cooling preservation device, the Controlled Hypothermic Organ Preservation System (CHOPS), aimed at facilitating the enrollment of the control arms of the OCS ENHANCE Heart Part B and OCS DENOVO Lung clinical trials. CHOPS will be regulated by the U.S. Food and Drug Administration (FDA) as a new, stand-alone device for controlled hypothermic preservation. Importantly, TransMedics will submit an Investigation Device Exemption (IDE) amendment to allow CHOPS to serve as the control arm for both Part B of ENHANCE Heart and DENOVO Lung Trials. if approved, this approach would also expand TransMedics' product offerings to include true controlled active cooling preservation devices to serve a broader segment of heart and lung transplant patients globally, based on prospective level 1 evidence. $TMDX enters in cooling preservation devices market as at the end of trials, they will have clinical evidence for OCS2.0 superiority AND alternative offering of Product that dominate DBD market today. So most probably, $TMDX will get PMI post trials for OCS2.0 and CHOPS.
English
$TMDX ‘Igloo’ box companies refused to provide their device to participate in OCS2.0 trials comparison for DBD Heart and Lung. Guess what Waleed did? Today TransMedics will unveil its new controlled, active cooling preservation device, the Controlled Hypothermic Organ Preservation System (CHOPS), aimed at facilitating the enrollment of the control arms of the OCS ENHANCE Heart Part B and OCS DENOVO Lung clinical trials.
CHOPS will be regulated by the U.S. Food and Drug Administration (FDA) as a new, stand-alone device for controlled hypothermic preservation. Importantly, TransMedics will submit an Investigation Device Exemption (IDE) amendment to allow CHOPS to serve as the control arm for both Part B of ENHANCE Heart and DENOVO Lung Trials.
if approved, this approach would also expand TransMedics' product offerings to include true controlled active cooling preservation devices to serve a broader segment of heart and lung transplant patients globally, based on prospective level 1 evidence.
$TMDX enters in cooling preservation devices market as at the end of trials, they will have clinical evidence for OCS2.0 superiority AND alternative offering of Product that dominate DBD market today. So most probably, $TMDX will get PMI post trials for OCS2.0 and CHOPS.
English
@WealthyReadings all good but it is very sad seeing $TMDX labeled as loser!! :)
English
Rapid reflection on the importance of selling losers.
I always closed my positions on one key metric: price action. If a stock doesn't hold its uptrend, I am out. Something not many around here believe to be a good method.
But let's review if it was worth it.
$ALAB at $130 in February - One of the hardest sells I had to do these last months as I was convinced to be right; that their new optical acquisition was a great fit to match their core business and the current demand for AI hardware.
x.com/WealthyReading…
The stock surged as the market woke up to opticals and is now up ~42% since I sold.
$TMDX at $114 in March - another tough sell for the same reason within a different sector. I am sure the stock will rocket as the company is executing perfectly and continues to increase its transplant market shares and the volume of transplants themselves due to its technology.
x.com/WealthyReading…
The stock is flat since.
$BABA at $135 in March - This one was sold on both fundamentals and price action as besides breaking its W50, earnings also showed a large CapEx spending on its e-com platform and that shouldn't have been the case in my thesis; AI was the only priority.
x.com/WealthyReading…
The stock is flat since.
And then come the big losers which I won't comment much on why I closed them as I have for months and nothing changed: fundamentals are maybe here, maybe not, narrative is in the gutter and price action is terrible.
$ADBE at $310, down 20% since.
$LULU at $170, flattish since.
$DUOL at $200, down 48% since.
$PATH at $14, down 25% since.
Those 7 positions yielded a weighted average performance of -7.3% since closed. This is what would have happened to my portfolio if I hadn't accepted the loss and moved liquidity onto strength.
On the contrary, growing my positions in $SOI $GFS $SILC $LUNR and having liquidity available to trade $AXTI $RKLB generated 85% gains over the last month.
This is the cost of ignoring price action, holding through thick and thin on biased convictions which the market doesn't care about.
Selling a loser is too underrated on here.
wealthyreadings.com/p/the-art-of-s…
English
@CalmInvestor Hello Anoop, may I request you to please write a blog on your thoughts on how AI advances will impact different service business like IT Services, Financial, HR, Legal etc? and its domino effect like layoff, real estate slowdown and more?
appreciate you cover how capitalmind flexicap fund is planning to ride this angle?
@deepakshenoy @NihitKshatriya
English
@CalmInvestor Hello Anoop, been studing Capitalmind flexicap fund since last few months and monitoring how you are adjusting it based on evolving dynamics - very impressed. How can I reach out to ask couple of questions before I finally pull the trigger to invest. @NihitKshatriya @CapitalmindMF
English
Been part of this amazing community since few months!! Highly recommended…
SixSigmaCapital@SixSigmaCapital
Emergency medicine is my background, but the stock market is my Ikigai. After a decade of scaling my accounts, staying in medicine is becoming harder to justify. Opportunity cost I do have my SS and Discord also, join the free or paid versions of those.. Any Queries DM
English
@Stockspy1 even if it figures out or already it has, it will continue to hold or pump!! this is now out of hands until it isn't
English
Manthan Bhadiyadra รีทวีตแล้ว
PPI less than forecast. 🔽
FinancialJuice@financialjuice
⚠ BREAKING: US PPI YoY Actual 4% (Forecast 4.6%, Previous 3.4%)
English
@LogicalThesis @Investor_NICK_ My employer contributes 8% on my 6% so its no brainer for me to not continue.
English
@Investor_NICK_ Ngl I consider withdrawing our 401Ks
I think it's great for 99% of Americans
But for the people who are active like us and live in expensive cities
Been thinking about this for weeks, i plan to pause my contributions today
English
$TMDX I don’t want to say anything!! At the end numbers will speak for itself!! I am stunned with these numbers and folks sold this for fuel issue that is anyway passed to hospitals?
POLR@POLR_Investing
$TMDX March Transplant Update Huge month for DCD transplant volume with an all time high in both Liver and Heart. This is similar to last year where transplant volumes spiked in March and continued that momentum into Q2. - Total Transplant Volume: 1,747 (9% MoM, +2% YoY) - DCD Volume: 675 (22% MoM, +23% YoY) - DCD Share: 39% of total transplants (vs 32% in March 2025). As a reminder, to meet management's guidance for 2026, I am assuming DCD volume has to increase ~20% YoY, so well on track with YTD DCD volume up 36%. Total Transplant growth is somewhat tepid at 3% growth YTD. Would like to see that inch up closer to 4-5%. Revenue Estimate Based on DCD and Flight data I am assuming $175M for revenue in Q1 with potential upside of $180M. Looking ahead to Q2, historically Transmedics' best quarter, flight data is off to a prodigious pace averaging 35 flights a day. This pace will be needed because I do not think the Q1 results alone warrant a revenue raise from management.
English
$TMDX when I posted this, it was 313 flights and now it is 344!! Exactly 12 hours after!! 31 flights in 12 hours. I believe both Lung and DBD heart focused trials in full force now and guess what, both are green field areas to grow.
It has been painful last few weeks but I have held through despite chart breakdowns as I couldn’t find anything that is even remotely threatening my thesis. Next stop March transplant data so lookout for @POLR_Investing or @JayBahel monthly post and then will try earning prediction.
Manthan Bhadiyadra@ManthanTweets1
$TMDX Record flight day(52) and week!! Currently 313 flights avg 34 per day!!
English
$TMDX Record flight day(52) and week!! Currently 313 flights avg 34 per day!!
English
PPFAS Flexicap Fund has still cash of ₹27000 Cr.
They have not deployed the money in recent down.
Are they doing the right thing without deploying the investors' money?
English
HOME SELLERS SLASH PRICES AS BUYERS GAIN POWER
A record 34.2% of home sellers cut prices in February, up from 31.5% last year, according to Redfin.
Those who reduced prices dropped them by an average of $40,915 (7.3%), reflecting a clear shift to a buyer’s market.
High mortgage rates, elevated prices, and economic uncertainty are keeping buyers on the sidelines—leaving sellers with more competition and forcing price cuts.
English
Manthan Bhadiyadra รีทวีตแล้ว
Never forget: you can ALWAYS make a comeback at any point in your life.
English